The Nomination Committee of Boule Diagnostics AB has decided to propose to the Annual General Meeting 2025 (AGM) that the number of Board members shall be five (previous year six), including the Chair.
The Nomination Committee proposes re-election of Thomas Eklund, Rikke Rytter, Emil Hjalmarsson, Torben Jørgensen and Yvonne Mårtensson. Torben Jørgensen is proposed to be re-elected as the Chairman of the Board. Karin Dahllöf has decided to leave the Board.
Detailed information about the proposed Board members can be found on Boule’s website.
The Nomination Committee’s complete proposal for a decision to the 2025 AGM as well as their reasoned statement will be submitted at the latest in connection with the publication of the notice to the AGM.
For more information, please contact:
Erik Ivarsson, Chairman of the Nomination Committee erik.ivarsson@grenspecialisten.com ,
phone +46 (0)733-890 752
Torben Nielsen, CEO and Group President, torben.nielsen@boule.com, phone +46 (0)70-558 51 05
Holger Lembrér, CFO, holger.lembrer@boule.com , phone +46 (0)72-230 77 10
About Boule Diagnostics AB (publ)
Boule Diagnostics AB (publ) is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies to which it offers complete systems for blood diagnostics (hematology) in both the human and veterinary areas. Boule has strong positions in important emerging markets such as in Asia and in recent years has improved its position in the fast-growing veterinary market. Operations are conducted through operating subsidiaries in Sweden, the United States, Mexico and Russia. The Group reported net sales of SEK 559 million in 2024 and has more than 200 employees. Sales are conducted globally, predominantly through the company’s 200 or so distributors in over 100 countries, supported by Boule’s own local sales and service personnel. Boule has been listed on Nasdaq Stockholm since 2011. http://www.boule.com
This information was submitted for publication, through the agency of the contact person set out above, at 11:00 CET on February 26, 2025.
Nomination Committee’s proposal for Board members 2025 of Boule Diagnostics